Technical Analysis for MBIO - Mustang Bio, Inc.

Grade Last Price % Change Price Change
F 0.21 0.43% 0.00
MBIO closed down 5.3 percent on Wednesday, November 20, 2024, on 22 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.43%
Narrow Range Bar Range Contraction 0.43%
Wide Bands Range Expansion 0.43%
Oversold Stochastic Weakness 0.43%
Spinning Top Other -4.89%
Wide Bands Range Expansion -4.89%
Oversold Stochastic Weakness -4.89%
NR7 Range Contraction -4.59%
Narrow Range Bar Range Contraction -4.59%
Wide Bands Range Expansion -4.59%

   Recent Intraday Alerts

Alert Time
Up 2% 9 minutes ago
Fell Below Previous Day's Low about 3 hours ago
Down 2 % about 3 hours ago
Down 1% about 3 hours ago
Up 1% about 3 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mustang Bio, Inc. Description

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology, which uses the patient’s own T cells to engage and destroy specific tumors. The Company, through its agreement with City of Hope National Medical Center, is using three novel CAR T therapies in the development of cancer treatments, including human epidermal growth factor receptor 2 CAR T technology, CS1-specific CAR T technology, and prostate stem cell antigen CAR T technology.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immune System Immunotherapy Cancer Treatment Cancer Immunotherapy Gene Therapy Virotherapy Cancer Cell Epidermal Growth Factor Receptor T Cell Chimeric Antigen Receptor Immunotherapy Products Cancer Immunotherapy Product Cellectis

Is MBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.6781
52 Week Low 0.1281
Average Volume 1,862,739
200-Day Moving Average 0.49
50-Day Moving Average 0.24
20-Day Moving Average 0.26
10-Day Moving Average 0.24
Average True Range 0.03
RSI (14) 34.64
ADX 22.22
+DI 20.71
-DI 18.87
Chandelier Exit (Long, 3 ATRs) 0.29
Chandelier Exit (Short, 3 ATRs) 0.29
Upper Bollinger Bands 0.31
Lower Bollinger Band 0.20
Percent B (%b) 0.07
BandWidth 43.78
MACD Line -0.01
MACD Signal Line 0.00
MACD Histogram -0.0059
Fundamentals Value
Market Cap 1.75 Million
Num Shares 8.37 Million
EPS -8.93
Price-to-Earnings (P/E) Ratio -0.02
Price-to-Sales 0.00
Price-to-Book 3.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.23
Resistance 3 (R3) 0.23 0.22 0.22
Resistance 2 (R2) 0.22 0.22 0.22 0.22
Resistance 1 (R1) 0.22 0.22 0.21 0.21 0.22
Pivot Point 0.21 0.21 0.21 0.21 0.21
Support 1 (S1) 0.21 0.21 0.20 0.20 0.20
Support 2 (S2) 0.20 0.21 0.20 0.20
Support 3 (S3) 0.19 0.20 0.19
Support 4 (S4) 0.19